Veronica Pirriatore
Overview
Explore the profile of Veronica Pirriatore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
41
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lazzaro A, Vai D, Barco A, Stroffolini G, Pirriatore V, Guastamacchia G, et al.
J Acquir Immune Defic Syndr
. 2024 Sep;
97(2):180-191.
PMID: 39250652
Background: The pathogenesis of HIV-associated neurocognitive (NC) impairment is multifactorial, and antiretroviral (ARV) neurotoxicity may contribute. However, interventional pharmacological studies are limited. Methods: Single-blind, randomized (1:1), controlled trial to assess...
2.
Stroffolini G, Lazzaro A, Barco A, Pirriatore V, Vai D, Giaccone C, et al.
J Neuroimmune Pharmacol
. 2023 Oct;
18(4):551-562.
PMID: 37906406
The prevalence of neurocognitive impairment in people living with HIV is estimated between 30 and 50%. The pathogenesis of HIV-associated neurocognitive disorders is complex and multifactorial. Aim of the study...
3.
Trunfio M, Scabini S, Mornese Pinna S, Rugge W, Alcantarini C, Pirriatore V, et al.
Microorganisms
. 2021 Aug;
9(8).
PMID: 34442727
Pathocoenosis and syndemics theories have emerged in the last decades meeting the frequent need of better understanding interconnections and reciprocal influences that coexistent communicable and non-communicable diseases play in a...
4.
Trentalange A, Borgogno E, Motta I, Antonucci M, Pirriatore V, Costa C, et al.
Int J Antimicrob Agents
. 2021 Feb;
57(3):106297.
PMID: 33539932
Background: The treatment of drug-sensitive tuberculosis (TB) is highly effective; however, many patients have suboptimal drug exposure, which possibly explains treatment failures and selection of resistance. This study aimed to...
5.
Goletti D, Navarra A, Petruccioli E, Cimaglia C, Compagno M, Cuzzi G, et al.
Int J Infect Dis
. 2019 Dec;
92:62-68.
PMID: 31887456
Background: The Italian Society of Infectious and Tropical Diseases performed a survey on the application of guidelines for the management of persons living with HIV (PLWH), to evaluate current practice...
6.
Lupia T, Milia M, Atzori C, Gianella S, Audagnotto S, Imperiale D, et al.
AIDS
. 2019 Nov;
34(3):373-380.
PMID: 31764071
Objective: The current study aimed to investigate whether cerebrospinal fluid (CSF) Epstein-Barr virus (EBV) or cytomegalovirus (CMV) DNA was associated with viral, inflammatory and neuronal damage biomarkers in people living...
7.
Bertero L, Joseph S, Trunfio M, Allice T, Catera S, Imperiale D, et al.
AIDS
. 2019 Jan;
33(4):665-674.
PMID: 30608272
Objective: HIV infection chronically affects the central nervous system (CNS). Olfactory mucosa is a unique site in the respiratory tract that is directly connected to the CNS; thus we wanted...
8.
Scabini S, Trunfio M, Pirriatore V, Imperiale D, Audagnotto S, Bertucci R, et al.
Infez Med
. 2018 Jun;
26(2):160-163.
PMID: 29932090
A case of progressive multifocal leukoencephalopathy (PML) is described in an HIV-negative patient with mixed connective-tissue disease (MCTD) on a minimally immunosuppressive treatment with hydroxychloroquine. The patient presented with right-sided...
9.
Palazzo A, Trunfio M, Pirriatore V, Milesi M, De Nicolo A, Alcantarini C, et al.
J Antimicrob Chemother
. 2017 Dec;
73(3):826-827.
PMID: 29244118
No abstract available.
10.
Marinaro L, Calcagno A, Ripamonti D, Cenderello G, Pirriatore V, Trentini L, et al.
J Clin Virol
. 2016 Dec;
87:30-36.
PMID: 27992788
Background: Unboosted atazanavir with raltegravir has been investigated at 300mg twice daily showing frequent hyperbilirubinemia and selection of resistance-associated mutations. Objectives: Atazanavir 200mg twice daily could increase tolerability and plasma...